Bruker (NASDAQ:BRKR) Sets New 52-Week Low – Should You Sell?

by · The Cerbat Gem

Bruker Co. (NASDAQ:BRKR – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $54.54 and last traded at $54.55, with a volume of 1524371 shares trading hands. The stock had previously closed at $55.92.

Analysts Set New Price Targets

BRKR has been the subject of several research analyst reports. TD Cowen decreased their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Wells Fargo & Company decreased their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Citigroup decreased their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Barclays decreased their target price on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $79.36.

Get Our Latest Analysis on Bruker

Bruker Trading Down 2.6 %

The firm has a market cap of $8.26 billion, a P/E ratio of 26.88, a P/E/G ratio of 2.68 and a beta of 1.20. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The firm has a 50 day simple moving average of $63.07 and a 200 day simple moving average of $65.69.

Bruker (NASDAQ:BRKR – Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same period last year, the firm earned $0.74 earnings per share. On average, equities research analysts predict that Bruker Co. will post 2.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Bruker

A number of large investors have recently bought and sold shares of the stock. Covestor Ltd increased its stake in shares of Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the period. First Horizon Advisors Inc. increased its stake in shares of Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares during the period. UMB Bank n.a. increased its stake in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Bruker during the second quarter valued at approximately $52,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Bruker by 40.7% during the first quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock valued at $81,000 after buying an additional 248 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

(Get Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Read More